Literature DB >> 19332708

Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors?

Aristotle Bamias, George Lainakis, Efstathios Manios, Eleni Koroboki, Alexandra Karadimou, Nikos Zakopoulos, Meletios A Dimopoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19332708     DOI： 10.1200/JCO.2008.21.6028

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Confusion of therapeutic approaches.

Authors:  Philipp Ivanyi; Viktor Grünwald
Journal:  Dtsch Arztebl Int       Date:  2014-05-30       Impact factor: 5.594

2.  An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.

Authors:  Olivier Mir; Romain Coriat; Laure Cabanes; Stanislas Ropert; Bertrand Billemont; Jérôme Alexandre; Jean-Philippe Durand; Jean-Marc Treluyer; Bertrand Knebelmann; François Goldwasser
Journal:  Oncologist       Date:  2011-08-01

3.  Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.

Authors:  John D Groarke; Toni K Choueiri; David Slosky; Susan Cheng; Javid Moslehi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09

Review 4.  Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma.

Authors:  Lisa Derosa; Hassane Izzedine; Laurence Albiges; Bernard Escudier
Journal:  Oncol Rev       Date:  2016-11-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.